07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

T cell gas, tumor brake

  A trio of studies has converged on a common pathway, headed by the PPAR co-activator PGC-1α , to fight cancer and chronic infections by manipulating either T cell immunotherapies or the tumors themselves. While...
07:00 , Oct 20, 2016 |  BC Innovations  |  Product R&D

Sirtuins forge ahead

Since sirtuins hit the scene as modulators of numerous cellular pathways over 20 years ago, the enzymes have been implicated in metabolic diseases, aging and cancer. Now Forge Life Science LLC has licensed findings from...
07:00 , Mar 25, 2013 |  BioCentury  |  Finance

Done with biotech

Done with biotech...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Company News

GlaxoSmithKline pharmaceuticals news

GlaxoSmithKline said it will close its Sirtris Pharmaceuticals Inc. facility in Cambridge, Mass., and integrate the Discovery Performance Unit (DPU), which has been studying sirtuins, into the pharma's site in Upper Providence, Pa. GSK, which...
00:36 , Mar 13, 2013 |  BC Extra  |  Company News

GSK to close Sirtris Pharmaceuticals site

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will close its Sirtris Pharmaceuticals Inc. facility in Cambridge, Mass. and integrate the sirtuin Discovery Performance Unit (DPU) into the pharma's Upper Providence, Pa., site. GSK, which has about...
08:00 , Nov 5, 2012 |  BioCentury  |  Finance

Skyline's limit

Skyline's limit Skyline Ventures isn't talking about its decision to suspend fundraising for a sixth fund, but its performance compared to other healthcare VCs shows just how hard it is to raise money these days....
07:00 , Sep 20, 2012 |  BC Innovations  |  Targets & Mechanisms

ASIRTaining a Parkinson's disease target

A Tufts University team has compelling evidence that reducing sirtuin 2 activity could be beneficial in Parkinson's disease. 1 The findings argue for developing brain-penetrating sirtuin 2 inhibitors. Sirtuin 2 ( SIRT2 ) is one...
07:00 , May 17, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Emphysema Sirtuin 1 (SIRT1) Mouse studies suggest activating SIRT1 could help treat emphysema. In mice, Sirt1 knockout in airway epithelium...
08:00 , Feb 16, 2012 |  BC Innovations  |  Targets & Mechanisms

Still un-sirtuin

Researchers at the NIH have proposed a new mechanism to explain the beneficial metabolic effects of resveratrol, a polyphenol compound from red wine thought by many to act primarily on sirtuin 1 . The NIH...
08:00 , Feb 13, 2012 |  BioCentury  |  Finance

Calculating ChemoCentryx

The experience of ChemoCentryx Inc. provides more evidence that preclinical-stage Verastem Inc. 's bumped up IPO and $202.3 million valuation isn't a measuring stick for biotechs looking to go public. Indeed, investors took a pound...